Jannah Theme License is not validated, Go to the theme options page to validate the license, You need a single license for each domain name.
Business

GOODMIND™ Available in UK and Europe – Exclusive Distribution Agreement Signed for This Title, Canadian Business Journal

TORONTO, November 29, 2022 (GLOBE NEWSWIRE) — Psyence Group Inc. (CSE: PSYG | OTCQB: PSYGF) (“science” or “Company), a life sciences biotechnology company pioneering the use of natural psychedelics in mental health and well-being, along with joint venture partner The Goodleaf Company (Pty) Ltd (“Goodleaf”), announces its entry. I am happy to announce.enter into an exclusive distribution agreement with This Works Products Limited (“This Works”), regarding the distribution and sale of the functional mushroom brand of the joint venture, Goodmin™in the UK and Europe.

This Works is one of the UK’s leading skin care and wellbeing companies and in line with an exclusive distribution agreement, This Works will launch GOODMIND™ Functional Mushroom Capsules through the This Works website (www.thisworks.com) in November. to start selling. 2022. In the first quarter of 2023, Good Minds sachets will also be available on his This Works, his website and select retailers.

“In line with our strategy to expand our functional mushroom product offerings beyond South Africa, we are pleased to extend the availability of GOODMIND™ functional mushroom products to the UK and Europe. The GOODMIND™ Being the first functional mushroom product available through This Works, in a market we believe has a significant potential consumer base,To tell Dr. Neil Maresky, CEO of Psyence.

“We believe we will see significant growth in the field of functional mushrooms and will leverage our branding and marketing expertise, along with Psyence, its world-class scientific team, and the technical prowess of This Works to We look forward to launching GOODMIND™ in what we believe to be a strategic market for our products.” Goodleaf Founder and CEO Warren Schewitz said:.

“At This Works, we look at health holistically. , advocates for products that work closely with wellness solutions, and GOODMIND™’s premium functional mushroom formula is a perfect example.” To tell Dr. Anna Persaud, CEO of This Works.

GOODMIND™ Functional Mushroom Formula harnesses the power of adaptogens. A non-psychoactive fungus that has been used in traditional medicine for centuries to reduce stress.His GOODMIND™ products in capsule form and sachets are sold in South Africa through www.foragoodmind.com and are now www.foragoodmind.com. Sold in the UK and Europe via .thisworks.com.

The company further announces that Gavin Basserabie has tendered his effective resignation from the board of directors, although as a founder he continues to have a strong interest in the company. We thank Gavin for his contributions to the Board.

Our Board of Directors consists of Jody Aufrichtig, Dr. Neil Malesky, Alan Friedman and Marvin Singer.

ABOUT PSYENCE GROUP: www.psynce.com

Psyence is a Canadian Stock Exchange (CSE: PSYG) and OTCQB (OTCQB: PSYGF) life sciences biotechnology company focused on natural psychedelics. Science uses natural psilocybin products to heal trauma and its effects on mental health in the context of palliative care.Our name “Psyence” is a combination of words psychedelic When Science Affirming our commitment to producing psychedelic drugs developed through evidence-based research.

Guided by information from nature and science, the company built and operates one of the world’s first federally licensed commercial psilocybin mushroom cultivation and production facilities in South Africa. Our team brings international experience in both business and science and includes experts in mycology, neurology, palliative care, and drug development. We are committed to developing advanced natural psilocybin products for clinical research and development.

Our main divisions, Psyence Production, Psyence Therapeutics, and Psyence Function, support international collaborations with operations in Canada, the United Kingdom, South Africa, and a presence in the United States and Australia.

About Goodleaf: www.goodleaf.com

The Goodleaf Company is Africa’s largest vertically integrated cannabis business. Founded in 2019 and headquartered in Cape Town, the company creates world-class lifestyle, wellness and healthcare products for global distribution. We have 30 premium products to create harmony between mind and body in skincare, supplements and beverage categories. We are committed to finding the greenest solutions at every stage of the process. By 2022, we will have removed more than 85% of the plastic used throughout our products, transitioning to greener alternatives such as aluminum, glass and cork, and all paper packaging will be FSC certified. , printed with biodegradable inks. Our range is available in South Africa and the UK.

In 2021, Goodleaf acquired Canopy Growth’s medical cannabis facility in Lesotho. This happens to be Africa’s largest outdoor growing facility, with a total area of ​​200 hectares, and is both GACP and ISO22000 certified.

About this work

Founded in 2003 and with an international footprint spanning Europe, North America, the Middle East, Asia and Australia, This Works creates smart, natural products that work in sync with your body clock to maximize health and skin performance around the clock. A skincare brand. one day. This Works combines our knowledge of biological clocks and skin health with modern lifestyle learning to develop skincare and wellness essentials that support a busy life that starts with a good night’s sleep.

At the heart of each This Works product is a super blend. This is a powerful trio of natural actives, botanicals and essential oils, each selected for their specific benefits and expertly blended without unnecessary chemicals. All products are free of phthalates, sulfates, synthetic colors and fragrances, parabens, GMOs, mineral oil, petroleum jelly and propylene glycol.

Market leader in developing natural sleep solutions with over 9 million pillow sprays sold worldwide and over 16.5k 5-star ratings – This Works Pillow Spray was voted 6 by over 900 participants It has undergone two independent user trials and clinical studies.

contact address

Catherine Murphy, Investor Relations
Email: [email protected]
Media inquiries: [email protected]
general information: [email protected]

Future outlook:

Certain statements in this news release relating to Psyence Group Inc and its subsidiaries (collectively, the “Company”) are forward-looking statements and are forward-looking in nature. Forward-looking statements are based on current expectations and projections of future events rather than on historical facts and, therefore, actual results may differ materially from future results expressed or implied by the forward-looking statements. Subject to risks and uncertainties that may vary. These statements generally use terms such as “may”, “should”, “may”, “intend”, “estimate”, “plan”, “forecast”, ” It can be identified using forward-looking words such as “expect” and “believe”. ‘ or ‘Continue’, or the negative thereof, or similar variations. Forward-looking statements in this news release include statements regarding: This Works customer base recognized sizes, UK sizes, and european Market, and Growing Global Demand for Wellness ProductsThese forward-looking statements are based on a number of assumptions made by GOODMIND, including the following. The products are well received in the UK and Europe. There are a number of risks and uncertainties that could cause actual results and our plans and objectives to differ materially from those expressed in forward-looking information. These risks and uncertainties include lower-than-anticipated demand for our securities, changes in the price of our common stock, and our failure to raise anticipated amounts or the complete lack of funds. Including what was not procured. Actual results and future events could differ materially from those projected by such information. These and all subsequent written and oral forward-looking information are based on management’s estimates and opinions as of the date they were prepared and are expressly qualified in their entirety by this notice. We do not intend to update these forward-looking statements except as required by law.

We make no claims of medical, therapeutic, or health benefits for the products we suggest. The efficacy of psilocybin, psilocybin analogs, or other psychedelic compounds or dietary supplements remains the subject of ongoing research. There is no guarantee that any disease or condition can be diagnosed, treated, cured or prevented. Vigorous scientific research and clinical trials are required. We have not conducted any clinical trials regarding the use of the proposed product. References to the quality, consistency, efficacy and safety of a potential product do not imply that we have validated it in clinical trials or that we have completed such trials. If we are unable to obtain the approvals and research necessary for commercialization, our results of operations and operations could be materially and adversely affected.


CBJ Newsmaker

GOODMIND™ Available in UK and Europe – Exclusive Distribution Agreement Signed for This Title, Canadian Business Journal

Source link GOODMIND™ Available in UK and Europe – Exclusive Distribution Agreement Signed for This Title, Canadian Business Journal

Related Articles

Back to top button